Preferred Label : heterocyclic compounds, 3-ring;
MeSH definition : A class of organic compounds containing three ring structures, one of which is made
up of more than one kind of atom, usually carbon plus another atom. The heterocycle
may be either aromatic or nonaromatic; A class of heterocyclic compounds that include a three-ring fused structure. Both
aromatic or non-aromatic ring structures are included in this category.;
MeSH synonym : 3-ring heterocyclic compounds; heterocyclic cpds, 3 ring; heterocyclic compounds, 3 ring; Fused Heterocyclic Compounds, Three-Ring; Fused Heterocyclic Compounds, Three Ring; Three Ring Heterocyclic Compounds;
CISMeF synonym : compounds, 3-ring heterocyclic;
MeSH annotation : GEN; prefer specifics; used for mapping supplementary chemicals; general or unspecified; prefer specifics;
Is substance : O;
Origin ID : D006575;
UMLS CUI : C0019401;
Allowable qualifiers
Record concept(s)
Related MeSH Supplementary Concept(s)
- 1,2,2a,5,5a,6,7,8,8a-nonahydro-4,6,8-trimethylquinolizino(1,8-ae)pyrrole [MeSH Supplementary Concept]
- 12-chloro-14,14-diphenyl-2,6,11,13,15,16-hexaaza-1,12-diphosphatricyclo(10.3.1.0(1,6))hexadeca-12,14-diene, [MeSH Supplementary Concept]
- 2,12-dichloro-10,20-diphenyl-5,7,15,17-tetrahydro-6H,16H-dibenzo(d,l)(1,9,2,6,10,14)dioxotetraazacyclohexadecine-6,16-dione [MeSH Supplementary Concept]
- 3,6,9,16,19,22-hexaaza-6,19-bis(2-hydroxyethyl)tricyclo(22,2,2,2(11,14))triaconta-1,11,13,24,27,29-hexaene [MeSH Supplementary Concept]
- 6,7,9,10,12,13,20,21-octahydro-5H,14H-8,11,19,22-tetraoxa-5,14-diazadibenzo(a,g)cyclooctadecene [MeSH Supplementary Concept]
- 6,7,9,10,17,18,20,21-octahydro-16H,22H-5,8,11,19-tetraoxa-16,22-diazadibenzo(a,j)cyclooctadecene [MeSH Supplementary Concept]
- 6,7,9,10,17,18-hexahydro-5H,11H-8,16,19-trioxa-5,11-diazadibenzo(a,g)cyclopentadecene [MeSH Supplementary Concept]
- AG14447 [MeSH Supplementary Concept]
- ATPA18 [MeSH Supplementary Concept]
- AV200 [MeSH Supplementary Concept]
- BFF-816 [MeSH Supplementary Concept]
- BMS-341 [MeSH Supplementary Concept]
- BO-1012 [MeSH Supplementary Concept]
- BP-PM6 [MeSH Supplementary Concept]
- DH379 [MeSH Supplementary Concept]
- GTx 134 [MeSH Supplementary Concept]
- KF19418 [MeSH Supplementary Concept]
- KSQ-3 [MeSH Supplementary Concept]
- KSQ-4 [MeSH Supplementary Concept]
- KU59403 [MeSH Supplementary Concept]
- LG 186 [MeSH Supplementary Concept]
- MA242 [MeSH Supplementary Concept]
- MF-310 [MeSH Supplementary Concept]
- MK 2206 [MeSH Supplementary Concept]
- MNI-444 [MeSH Supplementary Concept]
- MRS4183 [MeSH Supplementary Concept]
- ONC206 [MeSH Supplementary Concept]
- ONC212 [MeSH Supplementary Concept]
- OTX015 [MeSH Supplementary Concept]
- Oxo63 [MeSH Supplementary Concept]
- PCS1055 [MeSH Supplementary Concept]
- PF1270A [MeSH Supplementary Concept]
- PF1270B [MeSH Supplementary Concept]
- PF1270C [MeSH Supplementary Concept]
- PS1145 [MeSH Supplementary Concept]
- S44563 [MeSH Supplementary Concept]
- SAN2589 [MeSH Supplementary Concept]
- SB1617 [MeSH Supplementary Concept]
- SC 24 [MeSH Supplementary Concept]
- SDX 308 [MeSH Supplementary Concept]
- SDX 309 [MeSH Supplementary Concept]
- SH-1028 [MeSH Supplementary Concept]
- ST-148 [MeSH Supplementary Concept]
- TAC-Red [MeSH Supplementary Concept]
- TH1020 [MeSH Supplementary Concept]
- TMC-264 [MeSH Supplementary Concept]
- TY-011 [MeSH Supplementary Concept]
- XAV939 [MeSH Supplementary Concept]
- dimeim [MeSH Supplementary Concept]
- lybalvi [MeSH Supplementary Concept]
- melem [MeSH Supplementary Concept]
- rhod-2 [MeSH Supplementary Concept]
- versiol [MeSH Supplementary Concept]
Semantic type(s)
A class of organic compounds containing three ring structures, one of which is made
up of more than one kind of atom, usually carbon plus another atom. The heterocycle
may be either aromatic or nonaromatic
A class of heterocyclic compounds that include a three-ring fused structure. Both
aromatic or non-aromatic ring structures are included in this category.
https://www.has-sante.fr/jcms/p_3293335/fr/tivicay-dolutegravir-sodique
2021
false
false
false
France
hiv infections
adult
adolescent
child
treatment outcome
insurance, health, reimbursement
dolutegravir
teratogens
pregnancy
evaluation of the transparency committee
dolutegravir sodium
HIV integrase inhibitors
dolutegravir
heterocyclic compounds, 3-ring
oxazines
piperazines
pyridones
---
https://www.has-sante.fr/jcms/p_3266947/fr/rinvoq-upadacitinib-spondylarthrite-ankylosante
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
upadacitinib
spondylitis, ankylosing
adult
Delayed-Action preparations
antirheumatic agents
evaluation of the transparency committee
upadacitinib
heterocyclic compounds, 3-ring
---
https://ansm.sante.fr/tableau-atu-rtu/upadacitinib-15-mg-et-30-mg-comprime-a-liberation-prolongee
2021
false
false
false
France
French
guidelines for drug use
summary of product characteristics
package leaflet
upadacitinib
upadacitinib
administration, oral
Delayed-Action preparations
upadacitinib
adult
adolescent
dermatitis, atopic
Janus Kinase Inhibitors
Janus Kinase Inhibitors
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
---
https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
upadacitinib
upadacitinib
upadacitinib
adult
arthritis, rheumatoid
drug therapy, combination
antirheumatic agents
antirheumatic agents
administration, oral
Janus Kinase Inhibitors
Janus Kinase Inhibitors
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
arthritis, psoriatic
spondylitis, ankylosing
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
---
https://www.has-sante.fr/jcms/p_3181658/fr/rinvoq
2020
false
false
false
France
treatment outcome
upadacitinib
upadacitinib
administration, oral
upadacitinib
insurance, health, reimbursement
antirheumatic agents
antirheumatic agents
adult
arthritis, rheumatoid
drug therapy, combination
Janus Kinase Inhibitors
Janus Kinase Inhibitors
evaluation of the transparency committee
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
---
https://www.has-sante.fr/jcms/p_3146844/fr/dovato
2020
false
false
false
France
lamivudine and dolutegravir
drug combinations
dolutegravir
administration, oral
treatment outcome
lamivudine
hiv infections
HIV-1
adult
adolescent
reverse transcriptase inhibitors
anti-hiv agents
HIV integrase inhibitors
evaluation of the transparency committee
heterocyclic compounds, 3-ring
---
https://www.ema.europa.eu/en/medicines/human/EPAR/dovato
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
dolutegravir
dolutegravir
drug approval
europe
HIV integrase inhibitors
HIV integrase inhibitors
lamivudine
lamivudine
drug combinations
adult
adolescent
hiv infections
administration, oral
reverse transcriptase inhibitors
reverse transcriptase inhibitors
anti-hiv agents
anti-hiv agents
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
lamivudine and dolutegravir
drug evaluation, preclinical
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/dovato-infection-vih-4797.html
2019
false
false
false
Canada
French
drug evaluation
drug combinations
dolutegravir
HIV integrase inhibitors
lamivudine
administration, oral
reverse transcriptase inhibitors
hiv infections
HIV-1
Cost-Benefit analysis
lamivudine and dolutegravir
heterocyclic compounds, 3-ring
---
https://www.has-sante.fr/portail/jcms/c_2869239/fr/juluca
https://www.has-sante.fr/portail/jcms/c_2869239/fr/juluca-dolutegravir/rilpivirine-association-d-antiviraux
2018
false
false
false
France
French
drug combinations
dolutegravir and rilpivirine
treatment outcome
HIV integrase inhibitors
reverse transcriptase inhibitors
hiv infections
HIV-1
adult
administration, oral
evaluation of the transparency committee
guidelines for drug use
dolutegravir
Rilpivirine
heterocyclic compounds, 3-ring
dolutegravir, rilpivirine drug combination
---
New safety information for women using dolutegravir, a medication used to treat HIV
infection
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/67010a-fra.php
2018
false
false
false
Canada
French
English
neural tube defects
pregnancy
dolutegravir
dolutegravir
HIV integrase inhibitors
hiv infections
abnormalities, drug-induced
pregnancy trimester, first
infant, newborn
administration, oral
drug combinations
lamivudine, abacavir and dolutegravir
dolutegravir and rilpivirine
patient education handout
heterocyclic compounds, 3-ring
---
TIVICAY, TRIUMEQ and JULUCA (dolutegravir containing medicines) – Possible Risk of
Neural Tube Defects
Destinataires : Professionnels de la santé, y compris spécialistes des maladies infectieuses,
spécialistes du virus de l’immunodéficience humaine (VIH) et infirmiers(ères), virologues
cliniques, obstétriciens(ennes), gynécologues, pédiatres, spécialistes de la santé
sexuelle, pharmaciens(ennes) et omnipraticiens(ennes).
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2018/66998a-fra.php
2018
false
false
false
Canada
French
English
pharmacovigilance note
neural tube defects
pregnancy
dolutegravir
dolutegravir
HIV integrase inhibitors
hiv infections
abnormalities, drug-induced
guidelines for drug use
pregnancy trimester, first
infant, newborn
administration, oral
drug combinations
lamivudine, abacavir and dolutegravir
dolutegravir and rilpivirine
heterocyclic compounds, 3-ring
dolutegravir, rilpivirine drug combination
Abacavir/Dolutegravir/Lamivudine
Rilpivirine
---
https://www.ansm.sante.fr/actualites/anomalies-de-fermeture-du-tube-neural-chez-les-enfants-nes-de-meres-traitees-par-le-dolutegravir-pendant-la-grossesse
2018
false
false
false
France
French
pharmacovigilance note
neural tube defects
pregnancy
dolutegravir
dolutegravir
HIV integrase inhibitors
hiv infections
abnormalities, drug-induced
guidelines for drug use
pregnancy trimester, first
infant, newborn
administration, oral
drug combinations
lamivudine, abacavir and dolutegravir
dolutegravir and rilpivirine
Obstetrician (occupation)
Gynecologist (occupation)
Sexual Health
heterocyclic compounds, 3-ring
---
https://www.ema.europa.eu/medicines/human/EPAR/Juluca
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Rilpivirine
dolutegravir
drug combinations
dolutegravir and rilpivirine
drug approval
europe
treatment outcome
HIV integrase inhibitors
HIV integrase inhibitors
reverse transcriptase inhibitors
reverse transcriptase inhibitors
hiv infections
HIV-1
adult
administration, oral
product surveillance, postmarketing
drug monitoring
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
dolutegravir
Rilpivirine
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
dolutegravir, rilpivirine drug combination
dolutegravir, rilpivirine drug combination
---
https://www.has-sante.fr/portail/jcms/c_2801228/fr/tivicay-dolutegravir-inhibiteur-de-l-integrase
https://www.has-sante.fr/portail/jcms/c_2801228/fr/tivicay
2017
false
false
false
France
French
evaluation of the transparency committee
dolutegravir sodium
dolutegravir sodium
dolutegravir
dolutegravir
dolutegravir
administration, oral
hiv infections
HIV-1
adolescent
drug therapy, combination
HIV integrase inhibitors
HIV integrase inhibitors
treatment outcome
insurance, health, reimbursement
drug resistance, viral
guidelines for drug use
child
continuity of patient care
human immunodeficiency virus i infection
Genotype drug resistance test
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64287253
2015
false
false
false
France
French
summary of product characteristics
evaluation of the transparency committee
package leaflet
lamivudine, abacavir and dolutegravir
lamivudine
abacavir sulfate
dolutegravir sodium
drug combinations
abacavir
dolutegravir
dideoxynucleosides
heterocyclic compounds, 3-ring
---
http://www.has-sante.fr/portail/jcms/c_2008464/fr/triumeq
http://www.has-sante.fr/portail/jcms/c_2008464/fr/triumeq-dolutegravir/abacavir/lamivudine-association-fixe-d-antiretroviraux
2014
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
administration, oral
insurance, health, reimbursement
treatment outcome
drug combinations
dolutegravir
dolutegravir
abacavir
abacavir
lamivudine
lamivudine
lamivudine, abacavir and dolutegravir
reverse transcriptase inhibitors
reverse transcriptase inhibitors
anti-hiv agents
anti-hiv agents
HIV integrase inhibitors
HIV integrase inhibitors
adult
adolescent
hiv infections
HIV-1
HLA-B*57:01 antigen
human immunodeficiency virus i infection
Contraindications, Procedure
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
dideoxynucleosides
dideoxynucleosides
HLA-B antigens
Contraindications, Drug
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62685155
2014
false
false
false
France
French
summary of product characteristics
package leaflet
dolutegravir
compression, nos
tablets
dolutegravir
dandruff
pill, nos
seborrhea sicca
dandruff
heterocyclic compounds, 3-ring
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64146217
2014
false
false
false
France
French
summary of product characteristics
simeprevir
simeprevir
capsules
heterocyclic compounds, 3-ring
sulfonamides
---
http://www.has-sante.fr/portail/jcms/c_1748396/fr/tivicay
http://www.has-sante.fr/portail/jcms/c_1748396/fr/tivicay-50-mg-dolutegravir-inhibiteur-de-lintegrase
2014
false
false
false
France
French
evaluation of the transparency committee
dolutegravir sodium
dolutegravir sodium
dolutegravir
dolutegravir
dolutegravir
administration, oral
hiv infections
HIV-1
adult
adolescent
drug therapy, combination
HIV integrase inhibitors
HIV integrase inhibitors
treatment outcome
insurance, health, reimbursement
clinical trials as topic
drug resistance, viral
guidelines for drug use
heterocyclic compounds, 3-ring
heterocyclic compounds, 3-ring
---